Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT07144306
Recruiting Observational

AI-Driven Early Detection of Skin Cancer

NCT07144306 · tracked via the Priya Life Science UK tracker
Sponsor
Nuvana Healthcare LTD
Phase
Observational
Started
2025-10-01
Last updated
2025-09-26

Condition(s) studied

Skin Cancer Melanoma

Investigational drug(s) / intervention(s)

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Smartphone-based AI skin lesion analysis (NuvanaDx platform).: Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Study summary

This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.

Eligibility

Sex
ALL
Min age
18 Months
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Adults (≥18 years) presenting with skin lesions suspicious for malignancy. Ability to provide informed consent. Exclusion Criteria: Inability to provide informed consent. Poor-quality images unsuitable for AI analysis.

Primary outcome measure(s)

  • Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis — Time Frame: Up to 12 months
    Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis Time Frame: Up to 12 months Measure: Sensitivity, specificity, and predictive values

Trial sites (1)

FacilityCityRegionStatus
Nuvana Healthcare Ltd London United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07144306 on ClinicalTrials.gov ↗ ← All trials in the UK